E
ALT icon

Ergoteles’s Altimmune ALT Stock Holding History

Ergoteles’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-42,122
Closed -$178K – 1020
2023
Q1 		$178K Buy
+42,122
New +$500K 0.01% 1030
2022
Q3 		– Sell
-214,700
Closed -$2.51M – 1519
2022
Q2 		$2.51M Buy
+214,700
New +$1.32M 0.08% 266
2021
Q2 		– Sell
-18,100
Closed -$256K – 1468
2021
Q1 		$256K Buy
+18,100
New +$293K 0.01% 591

Other funds holding ALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Ergoteles's ALT Position: Q2 2023 in Review

Ergoteles sold out of Altimmune (ALT) in Q2 2023, closing a stake of 42,122 shares — an estimated $178K sold.

Ergoteles first reported a position in ALT in Q1 2021 and held it in 3 quarters. The position peaked at $2.51M in Q2 2022. 120 funds tracked by Wall St. Rank hold ALT as of Q2 2023.

  • Ergoteles reported no remaining Altimmune position as of Q2 2023 after selling out during the quarter.
  • Ergoteles sold 42,122 Altimmune shares in Q2 2023, an estimated $178K.
  • Ergoteles first reported a position in Altimmune in Q1 2021 and held it in 3 quarters.
  • Ergoteles's Altimmune position peaked at $2.51M in Q2 2022.
  • 120 funds tracked by Wall St. Rank held Altimmune as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.